FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315865211> ?p ?o ?g. }

• W4315865211 endingPage "7" @default.
• W4315865211 startingPage "5" @default.
• W4315865211 abstract "Future Medicinal ChemistryVol. 15, No. 1 EditorialLatest advances in specific inhibition of tumor-associated carbonic anhydrasesClaudiu T SupuranClaudiu T Supuran *Author for correspondence: E-mail Address: claudiu.supuran@unifi.ithttps://orcid.org/0000-0003-4262-0323Department of Neurofarba, Pharmaceutical & Nutraceutical Section, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, Florence, 50019, ItalySearch for more papers by this authorPublished Online:13 Jan 2023https://doi.org/10.4155/fmc-2022-0249AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: anticancer theragnostic agentcarbonic anhydrase IX/XIIferroptosishypoxic tumorsinhibitorsReferences1. Aspatwar A, Tolvanen MEE, Barker H et al. Carbonic anhydrases in metazoan model organisms: molecules, mechanisms, and physiology. Physiol. Rev. 102, 1327–1383 (2022).Crossref, Medline, CAS, Google Scholar2. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev. Drug Discov. 7, 168–181 (2008).Crossref, Medline, CAS, Google Scholar3. Kciuk M, Gielecińska A, Mujwar S et al. Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies. J. Enzyme Inhib. Med. Chem. 37(1), 1278–1298 (2022).Crossref, Medline, CAS, Google Scholar4. Nocentini A, Angeli A, Carta F et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J. Enzyme Inhib Med. Chem. 36, 561–580 (2021).Crossref, Medline, CAS, Google Scholar5. Kim D, Kim S, Park G, Choi H, Ryu JH. Spatiotemporal self-assembly of peptide amphiphiles by carbonic anhydrase IX- targeting induces cancer-lysosomal membrane disruption. JACS Au. 2(11), 2539–2547 (2022).Crossref, Medline, CAS, Google Scholar6. Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin. Sci. (Lond.) 135, 1233–1249 (2021).Crossref, Medline, CAS, Google Scholar7. Flaherty DP, Seleem MN, Supuran CT. Bacterial carbonic anhydrases: underexploited antibacterial therapeutic targets. Future Med. Chem. 13, 1619–1622 (2021).Link, Google Scholar8. De Luca V, Carginale V, Supuran CT, Capasso C. The Gram-negative bacterium Escherichia coli as a model for testing the effect of carbonic anhydrase inhibition on bacterial growth. J. Enzyme Inhib. Med. Chem. 37, 2092–2098 (2022).Crossref, Medline, Google Scholar9. Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J. Enzyme Inhib. Med. Chem. 31, 345–360 (2016).Crossref, Medline, CAS, Google Scholar10. Supuran CT. Carbonic anhydrase activators. Future Med. Chem. 10, 561–573 (2018).Link, CAS, Google Scholar11. Oehler S, Catalano M, Scapozza I et al. Affinity selections of DNA-encoded chemical libraries on carbonic anhydrase IX-expressing tumor cells reveal a dependence on ligand valence. Chemistry 27(35), 8985–8993 (2021).Crossref, Medline, CAS, Google Scholar12. Supuran CT. Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors. Expert Opin. Investig Drugs 30, 1197–1208 (2021).Crossref, Medline, CAS, Google Scholar13. McDonald PC, Chafe SC, Supuran CT, Dedhar S. Cancer therapeutic targeting of hypoxia induced carbonic anhydrase IX: from bench to bedside. Cancers (Basel) 14, 3297 (2022).Crossref, Medline, CAS, Google Scholar14. Chafe SC, Vizeacoumar FS, Venkateswaran G et al. Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. Sci. Adv. 7, eabj0364 (2021).Crossref, Medline, CAS, Google Scholar15. McDonald PC, Chia S, Bedard PL et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am. J. Clin. Oncol. 43, 484–490 (2020).Crossref, Medline, CAS, Google Scholar16. Millul J, Krudewig C, Zana A et al. Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX. Mol. Cancer Ther. 20(3), 512–522 (2021).Crossref, Medline, CAS, Google Scholar17. Liguori F, Carradori S, Ronca R et al. Benzenesulfonamides with different rigidity-conferring linkers as carbonic anhydrase inhibitors: an insight into the antiproliferative effect on glioblastoma, pancreatic, and breast cancer cells. J. Enzyme Inhib. Med. Chem. 37, 1857–1869 (2022).Crossref, Medline, CAS, Google Scholar18. Nerella SG, Singh P, Arifuddin M, Supuran CT. Anticancer carbonic anhydrase inhibitors: a patent and literature update 2018-2022. Expert Opin. Ther. Pat. 32, 833–847 (2022).Crossref, Medline, CAS, Google Scholar19. Kumar A, Siwach K, Supuran CT, Sharma PK. A decade of tail-approach based design of selective as well as potent tumor associated carbonic anhydrase inhibitors. Bioorg. Chem. 126, 105920 (2022).Crossref, Medline, CAS, Google Scholar20. Nannini G, De Luca V, D'Ambrosio C et al. A comparative study of carbonic anhydrase activity in lymphocytes from colorectal cancer tissues and adjacent healthy counterparts. J. Enzyme Inhib. Med. Chem. 37, 1651–1655 (2022).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 15, No. 1 STAY CONNECTED Metrics Downloaded 47 times History Received 10 October 2022 Accepted 12 December 2022 Published online 13 January 2023 Published in print January 2023 Information© 2023 Newlands PressKeywordsanticancer theragnostic agentcarbonic anhydrase IX/XIIferroptosishypoxic tumorsinhibitorsFinancial & competing interests disclosureResearch from the author's laboratory was financed by the Italian Ministry for University and Research (MIUR), grants PRIN prot. 2017XYBP2R and FISR2019_04819 BacCAD. The author declares conflict of interest, being one of the discoverers of SLC-0111. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W4315865211 created "2023-01-13" @default.
• W4315865211 creator A5035013697 @default.
• W4315865211 date "2023-01-01" @default.
• W4315865211 modified "2023-09-27" @default.
• W4315865211 title "Latest advances in specific inhibition of tumor-associated carbonic anhydrases" @default.
• W4315865211 cites W2047178318 @default.
• W4315865211 cites W2048937439 @default.
• W4315865211 cites W2186736649 @default.
• W4315865211 cites W3014500359 @default.
• W4315865211 cites W3117520927 @default.
• W4315865211 cites W3133227992 @default.
• W4315865211 cites W3158382892 @default.
• W4315865211 cites W3163437223 @default.
• W4315865211 cites W3192148209 @default.
• W4315865211 cites W3195000164 @default.
• W4315865211 cites W4200439189 @default.
• W4315865211 cites W4213041181 @default.
• W4315865211 cites W4225375522 @default.
• W4315865211 cites W4281777137 @default.
• W4315865211 cites W4281870802 @default.
• W4315865211 cites W4282825956 @default.
• W4315865211 cites W4283733841 @default.
• W4315865211 cites W4283837951 @default.
• W4315865211 cites W4288080824 @default.
• W4315865211 cites W4308566650 @default.
• W4315865211 doi "https://doi.org/10.4155/fmc-2022-0249" @default.
• W4315865211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36636980" @default.
• W4315865211 hasPublicationYear "2023" @default.
• W4315865211 type Work @default.
• W4315865211 citedByCount "3" @default.
• W4315865211 countsByYear W43158652112023 @default.
• W4315865211 crossrefType "journal-article" @default.
• W4315865211 hasAuthorship W4315865211A5035013697 @default.
• W4315865211 hasConcept C151730666 @default.
• W4315865211 hasConcept C181199279 @default.
• W4315865211 hasConcept C185592680 @default.
• W4315865211 hasConcept C2775914622 @default.
• W4315865211 hasConcept C2779343474 @default.
• W4315865211 hasConcept C55493867 @default.
• W4315865211 hasConcept C71924100 @default.
• W4315865211 hasConcept C86803240 @default.
• W4315865211 hasConceptScore W4315865211C151730666 @default.
• W4315865211 hasConceptScore W4315865211C181199279 @default.
• W4315865211 hasConceptScore W4315865211C185592680 @default.
• W4315865211 hasConceptScore W4315865211C2775914622 @default.
• W4315865211 hasConceptScore W4315865211C2779343474 @default.
• W4315865211 hasConceptScore W4315865211C55493867 @default.
• W4315865211 hasConceptScore W4315865211C71924100 @default.
• W4315865211 hasConceptScore W4315865211C86803240 @default.
• W4315865211 hasIssue "1" @default.
• W4315865211 hasLocation W43158652111 @default.
• W4315865211 hasLocation W43158652112 @default.
• W4315865211 hasOpenAccess W4315865211 @default.
• W4315865211 hasPrimaryLocation W43158652111 @default.
• W4315865211 hasRelatedWork W1967970523 @default.
• W4315865211 hasRelatedWork W1976336187 @default.
• W4315865211 hasRelatedWork W1987670445 @default.
• W4315865211 hasRelatedWork W1994421171 @default.
• W4315865211 hasRelatedWork W2015280585 @default.
• W4315865211 hasRelatedWork W2037909152 @default.
• W4315865211 hasRelatedWork W2116531544 @default.
• W4315865211 hasRelatedWork W2748952813 @default.
• W4315865211 hasRelatedWork W2899084033 @default.
• W4315865211 hasRelatedWork W4249578969 @default.
• W4315865211 hasVolume "15" @default.
• W4315865211 isParatext "false" @default.
• W4315865211 isRetracted "false" @default.
• W4315865211 workType "article" @default.